medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2023, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2023; 21 (1)

Toxic epidermal necrolysis and neutropenic fever: a case report

Gómez GMA, Loor GEM, Alcántara RVD, Gutiérrez ÁS

Language: Spanish
References: 19
Page: 24-28
PDF size: 219.20 Kb.


ABSTRACT

Toxic epidermal necrolysis is a dermatological emergency, multi-etiological with high mortality. The diagnosis of this condition is generally clinical with histopathological confirmation. We present a 19-year-old female who after an oral dose of piroxicam, initiated with prodromal symptoms, a generalized dermatosis, febrile neutropenia, and a fatal outcome. The presence of febrile neutropenia during toxic epidermal necrolysis is an important mortality factor, independent from the SCORTEN. A brief review is presented.


REFERENCES

  1. Schneider JA y Cohen PR, Stevens-Johnson syndrome and toxic epidermalnecrolysis: a concise review with a comprehensive summaryof therapeutic interventions emphasizing supportive measures, AdvTher 2017; 34(6):1235-44.

  2. Stevens AM, A new eruptive fever associated with stomatitis and ophthalmia:report of two cases in children, Am J Dis Child 1922; 24(6):526.

  3. Lyell A, Toxic epidermal necrolysis: an eruption resembling scalding ofthe skin, Br J Dermatol 1956; 68(11):355-61.

  4. Roujeau JC, Kelly JP et al., Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis, N Engl J Med 1995;333(24):1600-7.

  5. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, BouwesBavinck JN et al., Stevens-Johnson syndrome and toxic epidermalnecrolysis: assessment of medication risks with emphasis on recentlymarketed drugs. The Euroscar-study, J Invest Dermatol 2008; 128(1):35-44.

  6. Dodiuk-Gad RP, Chung WH, Valeyrie-Allanore L y Shear NH, Stevens-Johnson syndrome and toxic epidermal necrolysis: an update, Am JClin Dermatol 2015; 16(6):475-93.

  7. Stern RS y Divito SJ, Stevens-Johnson syndrome and toxic epidermalnecrolysis: associations, outcomes, and pathobiology: thirty yearsof progress but still much to be done, J Invest Dermatol 2017; 137(5):1004-8.

  8. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W,Roujeau J-C, et al., Correlations between clinical patterns and causesof erythema multiforme majus, Stevens-Johnson syndrome, and toxicepidermal necrolysis: results of an international prospective study,Arch Dermatol 2002; 138(8):1019-24.

  9. Quinn AM, Brown K, Bonish BK, Curry J, Gordon KB, Sinacore J etal., Uncovering histologic criteria with prognostic significance in toxicepidermal necrolysis, Arch Dermatol 2005; 141(6):6837.

  10. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J yWolkenstein P, scorten: a severity-of-illness score for toxic epidermalnecrolysis, J Invest Dermatol 2000; 115(2):149-53.

  11. Duplisea MJ, Roberson ML, Chrisco L, Strassle PD, Williams FN yZiemer CM, Performance of abcd-10 and scorten mortality predictionmodels in a cohort of patients with Stevens-Johnson syndrome/toxic epidermal necrolysis, J Am Acad Dermatol 2021; 85(4):873-7.

  12. Westly ED y Wechsler HL, Toxic epidermal necrolysis. Granulocyticleukopenia as a prognostic indicator, Arch Dermatol 1984; 120(6):721-6.

  13. Xang C-C y Tay Y-K, Hematological abnormalities and the use ofgranulocyte-colony-stimulating factor in patients with Stevens-Johnsonsyndrome and toxic epidermal necrolysis: patients with sjs andten, Int J Dermatol 2011; 50(12):1570-8.

  14. Yasui-Furukori N, Hashimoto K, Tsuruga K y Nakamura K, Comorbidityof Stevens-Johnson syndrome and neutropenia associated withlamotrigine: a case report, Gen Hosp Psychiatry 2014; 36(6):761.e9-11.

  15. Klastersky J, De Naurois J, Rolston K, Rapoport B, Maschmeyer G,Aapro M et al., Management of febrile neutropaenia: esmo ClinicalPractice Guidelines, Ann Oncol 2016; 27(suppl 5):v111-8.

  16. Su S-C, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S,Chen C-B et al., Interleukin-15 is associated with severity and mortalityin Stevens-Johnson syndrome/toxic epidermal necrolysis, J InvestDermatol 2017; 137(5):1065-73.

  17. Tsai T-Y, Huang I-H, Chao Y-C, Li H, Hsieh T-S, Wang H-H et al.,Treating toxic epidermal necrolysis with systemic immunomodulatingtherapies: a systematic review and network meta-analysis, J Am AcadDermatol 2021; 84(2):390-7.

  18. Charlton OA, Harris V, Phan K, Mewton E, Jackson C y Cooper A,Toxic epidermal necrolysis and Steven-Johnson syndrome: a comprehensivereview, Adv Wound Care 2020; 9(7):426-39.

  19. Castillo B, Vera N, Ortega-Loayza AG y Seminario-Vidal L, Woundcare for Stevens-Johnson syndrome and toxic epidermal necrolysis, JAm Acad Dermatol 2018; 79(4):764-7.e1.




2020     |     www.medigraphic.com